Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (13)

2024

  1. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

    Journal of Global Antimicrobial Resistance, Vol. 36, pp. 200-209

2023

  1. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Dalbavancin in clinical practice in Spain: A 2 year retrospective study

    JAC-Antimicrobial Resistance, Vol. 4, Núm. 6

2020

  1. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

  2. Safety and Tolerability of More than Six Days of Tedizolid Treatment

    Antimicrobial agents and chemotherapy, Vol. 64, Núm. 7

  3. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100

  2. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 3, pp. 194-195

2015

  1. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial

    BMJ Open, Vol. 5, Núm. 3

2009

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313